Stable Isotope Labeled Compounds Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

The stable isotope labeled compounds market is projected to witness a CAGR of nearly 3.3% over the forecast period.

The emergence of COVID-19 opened the doors for drastic R&D across the world. Companies were working hard to cope with the coronavirus and understand the effective way to manage the disease. The pandemic had a significant impact on the stable isotope-labeled compounds market as R&D was on the rise. For instance, in June 2020, Cambridge Isotobes Laboratory Inc. announced that the company was assisting the researchers at the Massachusetts Institute of Technology, Cambridge, to investigate the structure and dynamics of membrane proteins found in pathogenic viruses such as SARS-CoV 2 by supplying 3C6 glucose isotope which is used in E. coli-based protein expression to enrich SARS CoV 2 and also with 13C for the general requirement for NMR investigations of this type. As the use of stable isotopes labeled compounds increased for research during the pandemic, it is observed that the market was positively impacted. However, currently, the market is in its pre-pandemic phase and is expected to witness healthy growth in the coming years.

The major factor attributing to the growth of the market include the increase in the incidence of cancer and the growing investments in R&D programs by the biotechnology and pharmaceutical companies are boosting the market growth.

As per the data from the American Cancer Society report published in 2022, it is observed that there will be around 1.91 million new cancer cases in the United States during 2022. Among the cancer cases, cancers of the genital and digestive systems are expected to be the highest, with 395,600 and 343,040 new cases, respectively. The data published by PubMed in August 2021 stated that stable isotope tracing is an essential technology to study the molecular mechanisms by which nutraceuticals modulate and target cancer metabolism. Furthermore, the use of positionally labeled tracers as exogenous nutrients and the monitoring of their downstream metabolites labeling patterns enable the analysis of the specific metabolic pathway activity in cancer. Therefore, with the significance of stable isotopes in cancers, a high incidence of the disease is expected to propel market growth in the coming years.

Furthermore, there is growing research in the proteomics industry, which is augmenting the market growth. For instance, as per the data from the Journal of Proteomics and Bioinformatics data published in September 2022, rapid advancements in proteomics are enabling its high utilization in the treatment of infectious diseases across the world. Protein steady-state levels, protein turnover, and protein localization can all be determined using stable isotope labeling with mass spectrometry (MS)-based proteomic analysis. Hence, with the increasing research in proteomics research and the application of stable isotopes in the same, the market studied is expected to witness strong growth in the forecast period.

However, the high cost of the isotope compounds is the major drawback of the market.

Key Market Trends

Research and Development Segment is Dominating the Stable Isotope Labeled Compounds Market

The growth of the segment is attributed to the increase in R&D spending. Both government and major players are investing in product development. Stable isotope tracers can be safely governed simultaneously to the same subject without compromising future studies. The plasma volume which is needed from one sample to analyze the isotope enrichment is small, allowing even preterm infants to be studied.

The use of enriched stable isotopes and their applications as they are presently known emerges from early work with metabolites labeled with deuterium by Schoenheimer and Rittenberg in 1935. For the last two decades, enriched stable isotopes have offered substantial advantages to scientists and clinicians rapidly involved in the research on human body composition, pathogenies of several diseases, and understanding disease epidemiology.​ Increased awareness of the role played by the elements in human health and as etiologic factors in diseases (osteoporosis, heart disease, cancer, diabetes, kidney disease), as well as diagnostic and therapeutic adjuncts (obesity, inborn errors of metabolism, heart disease), has created an explosion in need for stable isotopes. ​

There is increasing activity among pharmaceutical companies in the isotope area. For instance, in August 2021, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator center, announced that the companies entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Additionally, in December 2021, AIkido Pharma Inc. announced that the company secured a strategic equity interest in ASP Isotopes Inc., which focuses on the non-nuclear supply of enriched isotopes. Hence, with such partnerships, the segment is expected to witness significant growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. The market growth is due to factors such as the presence of key players, the high prevalence of cancer in the region, and the established healthcare infrastructure. Furthermore, beneficial government initiatives and increased research partnerships are some of the drivers expected to propel market growth. The United States has the maximum share in this region due to supportive healthcare policies, the high number of patients, and a developed healthcare market.

There has been growing funding for research and development in stable isotopes in the United States. For instance, in October 2022, the US Secretary of Energy visited Oak Ridge National Laboratory to attend a groundbreaking ceremony for the US Stable Isotope Production and Research Center. The facility is slated to receive USD 75 million in funding from the Inflation Reduction Act. With such huge funding for stable isotopes, the market studied is expected to witness significant growth in the forecast period.

Furthermore, as per the data from Frontiers Journal published in August 2021, researchers in the United States are studying the use of stable isotopes in treating pancreatic cancer. The research on stable isotopes in the country is propelling the demand for the same and is contributing significantly to the market growth. Additionally, there is a growing burden of cancers in the United States which is augmenting the market growth.

Competitive Landscape

The stable isotope labelled compounds market is moderately competitive and consists of several major players. Some of the international companies that are present in this market are PerkinElmer Inc., Merck KGaA, Cambridge Isotope Laboratories Inc., JSC Isotope, Medical Isotopes Inc., Omicron Biochemicals Inc., Trace Sciences International, Alsachim, and Taiyo Nippon Sanso Corporation.

Additional benefits of purchasing the report:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.